These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 21614565)
1. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Alford SH; Toy K; Merajver SD; Kleer CG Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565 [TBL] [Abstract][Full Text] [Related]
2. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530 [TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672 [TBL] [Abstract][Full Text] [Related]
4. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of EZH2, paxillin expression and DNA ploidy of breast adenocarcinoma: correlation to pathologic predictors. Panousis D; Xepapadakis G; Lagoudianakis E; Karavitis G; Salemis N; Koronakis N; Patsouris E; Koronarchis D; Grosomanidis D; Chryssikos G; Ntasiou P; Kyriakidou V; Athanassiadou AM; Athanassiadou P J BUON; 2013; 18(4):879-85. PubMed ID: 24344012 [TBL] [Abstract][Full Text] [Related]
6. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH Oncology; 2004; 66(6):429-38. PubMed ID: 15452371 [TBL] [Abstract][Full Text] [Related]
7. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Wang H; Albadine R; Magheli A; Guzzo TJ; Ball MW; Hinz S; Schoenberg MP; Netto GJ; Gonzalgo ML Urol Oncol; 2012; 30(4):428-33. PubMed ID: 21396836 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma. Hayashi A; Morikawa T; Kawai T; Kume H; Ishikawa S; Homma Y; Fukayama M Virchows Arch; 2014 Apr; 464(4):463-71. PubMed ID: 24446035 [TBL] [Abstract][Full Text] [Related]
9. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950 [TBL] [Abstract][Full Text] [Related]
10. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma. Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715 [TBL] [Abstract][Full Text] [Related]
11. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues. Cao L; Sun PL; Yao M; Jia M; Gao H Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737 [TBL] [Abstract][Full Text] [Related]
12. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458 [TBL] [Abstract][Full Text] [Related]
13. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673 [TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis. Wang X; Hu B; Shen H; Zhou H; Xue X; Chen Y; Chen S; Han Y; Yuan B; Zhao H; Zhi Q; Kuang Y Biomed Pharmacother; 2015 Oct; 75():218-25. PubMed ID: 26271144 [TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. De Brot M; Rocha RM; Soares FA; Gobbi H Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210 [TBL] [Abstract][Full Text] [Related]
16. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features. Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214 [TBL] [Abstract][Full Text] [Related]
17. Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. Möllerström E; Kovács A; Lövgren K; Nemes S; Delle U; Danielsson A; Parris T; Brennan DJ; Jirström K; Karlsson P; Helou K BMC Cancer; 2010 Jun; 10():296. PubMed ID: 20553615 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Liu DC; Yang ZL Pathol Res Pract; 2011 Aug; 207(8):472-8. PubMed ID: 21719208 [TBL] [Abstract][Full Text] [Related]
19. BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma. Davidson B; Valborg Reinertsen K; Trinh D; Reed W; Bøhler PJ Hum Pathol; 2016 Aug; 54():64-73. PubMed ID: 27038683 [TBL] [Abstract][Full Text] [Related]
20. Invasive micropapillary carcinoma of the breast has a better long-term survival than invasive ductal carcinoma of the breast in spite of its aggressive clinical presentations: a comparison based on large population database and case-control analysis. Chen H; Wu K; Wang M; Wang F; Zhang M; Zhang P Cancer Med; 2017 Dec; 6(12):2775-2786. PubMed ID: 29072365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]